Metastatic renal cell carcinoma to the pancreas: experience of surgical treatment

Patyutko, Yu. I.; Котельников, А. Г.; Кригер, А Г; Проскуряков, И. С.; Galkin, G V; Polyakov, A. N.; Fainstein, I.

doi:10.17116/hirurgia201909125

Cited by 8 publications

(2 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…IsPMRCC are rare observations in which singular or multiple, synchronous or metachronous to the RCC distant metastases occur definitely or over a longer period exclusively in the pancreas. Since the last literature overview ( n = 1034) covering the years 1952 to 2019 [ 51 ] a further 173 isPMRCC observations could be added [ 27 , 28 , 52 , 53 , 54 , 55 , 56 , 57 , 58 , 59 , 60 , 61 , 62 ]. These 1207 observations serve as a basis for a literature review with meta-analysis.…”

Section: Ispmrccmentioning

confidence: 99%

Tumour Evolution and Seed and Soil Mechanism in Pancreatic Metastases of Renal Cell Carcinoma

Sellner

Thalhammer

Klimpfinger

2021

Cancers

View full text Add to dashboard Cite

In metastatic renal cell carcinoma, pancreatic metastases can appear in two clinical manifestations: (a) very rarely as isolated pancreatic metastases and (b) in the context with multi-organ metastatic disease. Both courses are characterised by rare, unusual clinical features. For isolated pancreatic metastases, the literature shows no effect on survival in all 11 publications that examined the effect of singular versus multiple pancreatic metastases; a lack of effect on survival time was also present in all 8 studies on pancreatic metastases size, in 7 of 8 studies on the influence of disease-free interval (DFI), and in 6 of 7 studies on the influence of synchronous versus metachronous metastases. In multi-organ site metastases observations, on the other hand, all five available references showed significantly better results in patients with concurrent pancreatic metastases compared to those without pancreatic metastases, although the total number of affected organs in the pancreatic metastases cohort was larger. Tumour volume-dependent risk factors thus remain surprisingly ineffective in both groups, which contradicts the usual behaviour of solid tumours. The reasons for this unusual behaviour and possible relations to tumour evolution and the hypothesis of an influence of a seed and soil mechanism in the occurrence of pancreatic metastases in metastatic renal cell carcinoma are discussed.

show abstract

Section: Ispmrccmentioning

confidence: 99%

Tumour Evolution and Seed and Soil Mechanism in Pancreatic Metastases of Renal Cell Carcinoma

Sellner

Thalhammer

Klimpfinger

2021

Cancers

View full text Add to dashboard Cite

show abstract

“…In a retrospective analysis of 54 patients with both synchronous and metachronous lesions undergoing surgical resection, 5-year survival was 74%. 2 Some of these series have demonstrated the proclivity of metastases to arise many years after the initial surgical management of the primary RCC. The majority of presentations occur within the first decade after nephrectomy; however, one retrospective review published in 2013 showed the mean time of presentation in a series of 42 patients was 11.2 years.…”

mentioning

confidence: 99%

Metastatic Renal Cell Carcinoma to the Pancreas Presenting 25 Years After Nephrectomy

Christopher

Pham

Grenn

et al. 2020

The American Surgeon

View full text Add to dashboard Cite

Pancreatic metastases from renal cancer: comparing surgery and pharmacotherapy efficacy

et al. 2020

Self Cite

View full text Add to dashboard Cite

Background. Today, targeted therapy is a standard treatment in advanced renal cell carcinoma, while the surgical method plays the role of a possible approach in a select category of patients with solitary and single metastases.The study objective to compare the effectiveness of two alternative treatment approaches: the surgical method and modern pharmacotherapy in achieving long-term overall survival of patients with pancreatic metastases of renal cell carcinoma.Materials and methods. A retrospective two-center study was conducted. The cohort of surgical treatment included patients (n = 56) who underwent surgery for pancreatic metastases from renal cell carcinoma at the N.N. Blokhin National Medical Research Center of Oncology and A.V. Vishnevsky National Medical Research Center of Surgery in the period from 1990 to 2019. Operations were performed for all types of pancreatic lesions: synchronous/metachronous, solitary/single and multiple, isolated/combined with lesions of other organs. Postoperative mortality rate was 5 % (3 patients). The pharmacotherapy cohort (n = 28) included patients with potentially resectable pancreatic metastases from clear cell renal cell carcinoma who underwent targeted therapy. Survival was assessed using the Kaplan–Mayer method. The Mantel–Cox test was used to test null hypothesis.Results. The 5-year overall survival rate was 68 % in the surgery group compared to 35 % for the pharmacotherapy group. Median overall survival for surgical and non-surgical patients was 82 months and 43 months, respectively (p = 0.01). The advantage of the surgical method was also found in a subgroup survival analysis of patients with extrapancreatic disease (p = 0.037). In this case, the 5-year overall survival rate was 66 % in the surgery subgroup (n = 25) compared to 35 % for the pharmacotherapy subgroup (n = 24). Conclusion. Radical surgical treatment in comparison with modern pharmacotherapy allows to achieve significantly higher rates of overall survival in patients with pancreatic metastases of renal cell carcinoma and can be considered as a priority.

show abstract

Metastatic renal cell carcinoma to the pancreas: experience of surgical treatment

Cited by 8 publications

References 12 publications

Tumour Evolution and Seed and Soil Mechanism in Pancreatic Metastases of Renal Cell Carcinoma

Tumour Evolution and Seed and Soil Mechanism in Pancreatic Metastases of Renal Cell Carcinoma

Metastatic Renal Cell Carcinoma to the Pancreas Presenting 25 Years After Nephrectomy

Pancreatic metastases from renal cancer: comparing surgery and pharmacotherapy efficacy

Contact Info

Product

Resources

About